Dr. James Kyle Bryan
Next up is clinical stage biopharmaceutical company VentiRx Pharmaceuticals who has announced the appointment of Dr. James Kyle Bryan as Chief Medical Officer.
With over 20 years of oncology drug discovery and development experience, Bryan “will be invaluable to VentiRx going forward” according to the company’s CEO Dr. Robert Hershberg. He added: “Kyle will be integral in directing our clinical development efforts.”
Bryan’s previous role was Vice President of Global Product Development at PPD, a CRO who last month bolstered its services in the US and Brazil. Read the story here.